edaravone has been researched along with CACH Syndrome in 1 studies
Excerpt | Relevance | Reference |
---|---|---|
"Edaravone treatment reduced differential VWMD protein expression of the UPR, phagosome regulation, ubiquitination, autophagy, ER stress, senescence, and TCA cycle pathways." | 1.91 | Edaravone and mitochondrial transfer as potential therapeutics for vanishing white matter disease astrocyte dysfunction. ( Carroll, L; Chung, J; Maksour, S; Newbery, M; Ng, NS; Ooi, L; Touffu, A; Wu, Y; Zaw, T, 2023) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Ng, NS | 1 |
Newbery, M | 1 |
Touffu, A | 1 |
Maksour, S | 1 |
Chung, J | 1 |
Carroll, L | 1 |
Zaw, T | 1 |
Wu, Y | 1 |
Ooi, L | 1 |
1 other study available for edaravone and CACH Syndrome
Article | Year |
---|---|
Edaravone and mitochondrial transfer as potential therapeutics for vanishing white matter disease astrocyte dysfunction.
Topics: Astrocytes; Edaravone; Eukaryotic Initiation Factor-2; Humans; Leukoencephalopathies; Mitochondria; | 2023 |